An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and
tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by
patients, parents and physicians, and its impact on self-esteem in adolescents (aged 12
through 17 years) with Attention-Deficit/Hyperactivity Disorder treated as outpatients in
Germany. An 8-week treatment phase is followed by a 16-week extension period.